Publications

Export 3643 results:
Sort by: Author [ Title  (Asc)] Type Year
A B [C] D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
Artaza, G. J., R. Z. Al Ansi, S. Sokolovic, G. Cerin, I. B. Munoz, C. Palombo, A. Panajotu, S. Moustafa, Y. Ashikhmin, M. Boutsikou, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 15, no. suppl 2: The Oxford University Press, pp. ii235–ii264, 2014. Abstract
n/a
Mora, B., D. Guldbrand, S. Fumagalli, P. M. Azcarate, H. Rus, T. Erdei, M. Cameli, S. Nistri, K. Hristova, B. Ivanovic, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 11, no. suppl 2: The Oxford University Press, pp. ii124–ii154, 2010. Abstract
n/a
Abdovic, E., K. Hristova, M. M. Gurzun, U. Canpolat, A. Gonella, H. Y. Seo, A. Nemes, R. Enache, D. Muraru, M. Cikes, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 14, no. suppl 2: The Oxford University Press, pp. ii67–ii95, 2013. Abstract
n/a
Mora, B., D. Guldbrand, S. Fumagalli, P. M. Azcarate, H. Rus, T. Erdei, M. Cameli, S. Nistri, K. Hristova, B. Ivanovic, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 11, no. suppl 2: The Oxford University Press, pp. ii124–ii154, 2010. Abstract
n/a
Abdovic, E., K. Hristova, M. M. Gurzun, U. Canpolat, A. Gonella, H. Y. Seo, A. Nemes, R. Enache, D. Muraru, M. Cikes, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 14, no. suppl 2: The Oxford University Press, pp. ii67–ii95, 2013. Abstract
n/a
N
Mahmoud, H., N. Bianchi, G.Bacco, and N. Chiodetto, " Nonlinear Analytical Computation of the Magnetic Field in Reluctance Synchronous Machines", IEEE Transactions on Industry Applications, vol. 53, issue 6, pp. 5373 - 5382, 2017.
A
Cerny V, Abdo I, G. R. B. M. S. L. L. N. C., " Analysis of microcirculation measurements by novice users trained by a standardized interactive tutorial: An inter-observer variability study.", Clin Hemorheol Microcirc, vol. 2016;62, issue (2), pp. 123-8. , 2016.
B
D
Canales Vergara, A. M., V. Landi, J. V. Delgado Bermejo, A. M. Martínez, P. Cervantes Acosta, A. P. Barros, D. Bigi, P. Sponenberg, M. Helal, M. Hossein Banabazi, et al., " Design and development of a multiplex microsatellite panel for the genetic characterisation and diversity assessment of domestic turkey (Meleagris gallopavo gallopavo)", Italian Journal of Animal Science , vol. 19, issue 1, pp. 392-398, 2020.
Parker, C. E., G. H. Degen, E. O. Abusteit, and F. T. Corbin, "The determination of metribuzin and its metabolites by high pressure liquid chromatography", Journal of liquid chromatography, vol. 4, pp. 725-742, 1983.
I
Mohamed, H. T., V. Untereiner, G. Cinque, S. A. A. Ibrahim, M. Götte, N. Q. Nguyen, R. Rivet, G. D. Sockalingum, and S. Brézillon, " Infrared Microspectroscopy and Imaging Analysis of Inflammatory and Non-Inflammatory Breast Cancer Cells and Their GAG Secretome ", Molecules, vol. 25, issue 18, pp. 4300, 2020. molecules-25-04300.pdf
M
Boukhary, Carter, Alsharhan, and M. F. Aly, " Maastrichtian echinoids from the Simsima Formation, northwestern Oman Mountains, UAE: a systematic view and ecological implications.", Revue Paléobiol., Genève, vol. 13, issue 2, pp. 577-595, 1999.
P
Farag, M. A., K. Schlangen, C. H. Carbonero, and D. Treutter, " Polyphenol metabolism provides a screening tool for beneficial effects of Onobrychis viciifolia (sainfoin). ", Phytochemistry, vol. 82, pp. 67-80., 2012. farag_et_al._2012_phytochemistry-b.pdf
S
Hassan, E. R., Y. G. Abdelhafez, M. A. Abougabal, C. Y. C Yeh, and C. Y. C Tseng, " SUVmax from 18F-FDG PET/CT may outperform volumetric biomarkers in assessment of primary tumor response to neoadjuvant chemoradiotherapy in patients with esophageal cancer", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 44 , pp. S278-S279, 2017.
Wong, D. C. J., R. Schlechter, A. Vannozzi, J. Holl, I. Hmmam, J. Bogs, G. B. Tornielli, S. D. Castellarin, and J. T. Matus, "A systems-oriented analysis of the grapevine R2R3-MYB transcription factor family uncovers new insights into the regulation of stilbene accumulation", DNA Research, vol. 23, issue 5, pp. 451-466, 2016.
(
Rezk, M., A. Chandra, D. Addis, H. Møller, M. Youssef, P. Dasgupta, and H. Yamamoto, "() expression as a predictor of oncological outcomes in patients with high-grade prostate cancer treated with primary androgen deprivation therapy: a cohort study.", BMJ open, vol. 9, issue 3, pp. e025161, 2019 Mar 08. Abstract

OBJECTIVES: To determine whether () expression can be used as a biomarker to predict biochemical recurrence and prostate cancer-specific death in patients with high Gleason grade prostate cancer treated with androgen deprivation therapy (ADT) as monotherapy.

METHODS: A multicentre retrospective cohort study identifying 149 patients treated with primary ADT for metastatic or non-metastatic prostate cancer with Gleason score 8-10 between 1999 and 2006. Patients planned for adjuvant radiotherapy at diagnosis were excluded. Age at diagnosis, ethnicity, prostate-specific antigen and Charlson-comorbidity score were recorded. Prostatic tissue acquired at biopsy or transurethral resection surgery was assessed for immunohistochemical expression of . Failure of ADT defined as prostate specific antigen nadir +2. Vital status and death certification data determined using the UK National Cancer Registry. Primary outcome measures were overall survival (OS) and prostate cancer specific survival (CSS). Secondary outcome was biochemical recurrence-free survival (BRFS).

RESULTS: The median OS of our cohort was 60.2 months (CI 52.0 to 68.3). expression observed in 51/149 cases (34%). Multivariate Cox proportional hazards analysis showed no significant association between expression and OS (p=0.41), CSS (p=0.92) and BRFS (p=0.31). Cox regression analysis showed Gleason score (p=0.003) and metastatic status (p<1×10) to be the only significant predictors of prostate CSS.

CONCLUSIONS: No significant association was found between status and any of our outcome measures. Despite a limited sample size, our results suggest that does not appear to be a useful biomarker in predicting response to ADT in patients with high risk prostate cancer.

,
El-Gamal, R., G. Abdel-Maksoud, Sawsan Darwish, Usama Saker, E. Topakas, and P. Christakopoulos, ", FTIR Analysis for the Evaluation of Some Triazole Fungicides for the Treatment of Wooden Artifacts", Mediterranean Archaeology and Archaeometry, vol. 18, issue 2, pp. 141-151 , 2018.
Pohlmann, K., J. B. Chapman, G. Pohll, A. E. Hassan, and P. Sanders, ", Integrating Numerical Modeling and Data Collection for Site Characterization at the Shoal Underground Nuclear Test Site, Nevada, USA", Spectrum 2002, 9th Biennial International Conference on Nuclear and hazardous Waste Management, Reno, Nevada, USA, 4 - 8 August, 2002.
-
.
1
l Burnett, M. N., R. Boothe, E. Clark, M. Gisin, H. M. Hassaneen, R. M. Pagni, G. Persy, R. J. Smith, and J. Wirz, "1,4-Perinaphthadiyl. Singlet- and Triplet-State Reactivity of a Conjugated Hydrocarbon Biradical.", J. Am. Chem. Soc. , vol. 110, pp. 2527-2538, 1988.
Pennell, D. J., J. B. Porter, A. Piga, Y. Lai, A. El-Beshlawy, K. M. Belhoul, M. Elalfy, A. Yesilipek, Y. Kilinç, T. Lawniczek, et al., "A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).", Blood, vol. 123, issue 10, pp. 1447-54, 2014 Mar 6. Abstract

Randomized comparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion dependent patients are lacking. CORDELIA was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneous deferoxamine (50-60 mg/kg per day for 5-7 days/week) for myocardial iron removal in 197 β-thalassemia major patients with myocardial siderosis (T2* 6-20 milliseconds) and no signs of cardiac dysfunction (mean age, 19.8 years). Primary objective was to demonstrate noninferiority of deferasirox for myocardial iron removal, assessed by changes in myocardial T2* after 1 year using a per-protocol analysis. Geometric mean (Gmean) myocardial T2* improved with deferasirox from 11.2 milliseconds at baseline to 12.6 milliseconds at 1 year (Gmeans ratio, 1.12) and with deferoxamine (11.6 milliseconds to 12.3 milliseconds; Gmeans ratio, 1.07). The between-arm Gmeans ratio was 1.056 (95% confidence interval [CI], 0.998, 1.133). The lower 95% CI boundary was greater than the prespecified margin of 0.9, establishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of deferasirox). Left ventricular ejection fraction remained stable in both arms. Frequency of drug-related adverse events was comparable between deferasirox (35.4%) and deferoxamine (30.8%). CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial iron removal. This trial is registered at www.clinicaltrials.gov as #NCT00600938.

Moawad, A. R., J. Zhu, I. Choi, and K. H. S. Campbell, "102 EFFECT OF DEMECOLCINE PRE-TREATMENT ON VIABILITY, TIMING OF FIRST POLAR BODY EXTRUSION, SPINDLE CONFIGURATION, AND SUBSEQUENT DEVELOPMENT OF OVINE OOCYTES VITRIFIED AT GERMINAL VESICLE STAGE", Reproduction, Fertility and Development, vol. 22, no. 1: CSIRO, pp. 210–211, 2009. Abstract
n/a
Christine, B., S. K. Wilson, R. Shamloul, and A. J. Bella, "1265 SIMULTANEOUS PLACEMENT OF AN INFLATABLE PENILE PROSTHESIS AND ADVANCE MALE SLING FOR ERECTILE DYSFUNCTION AND INCONTINENCE: ROBUST EFFICACY AND SAFETY DATA AT 2 YEAR FOLLOW-UP", The Journal of Urology, vol. 183, no. 4: Elsevier, pp. e490, 2010. Abstract
n/a
Tourism